Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

@article{Garst2005TopotecanIT,
  title={Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.},
  author={Jennifer W. Garst and Richard Buller and Stephen J. Lane and Jeffrey Crawford},
  journal={Clinical lung cancer},
  year={2005},
  volume={7 3},
  pages={
          190-6
        }
}
BACKGROUND Almost 70% of all patients with lung cancer in the United States are>65 years of age, and the incidence of small-cell lung cancer (SCLC) increases with age until the eighth decade of life. However, elderly patients are underrepresented in clinical trials and are often suboptimally treated. The validity of age as a prognostic factor for toxicity or survival remains controversial. PATIENTS AND METHODS To investigate the safety and efficacy of topotecan (an approved treatment for… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Management of recurrent small cell lung cancer.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2008
VIEW 1 EXCERPT
CITES BACKGROUND

Das kleinzellige Bronchialkarzinom

  • Wiener klinische Wochenschrift
  • 2007
VIEW 1 EXCERPT
CITES BACKGROUND

Topotecan: An evolving option in the treatment of relapsed small cell lung cancer

  • Therapeutics and clinical risk management
  • 2007
VIEW 1 EXCERPT
CITES BACKGROUND